2nd Annual Hit ID Summit

Identifying & Screening Hits in Drug Discovery

Optimizing Hit Identification & Screening Strategies Using DELs, ASMS, Chemical Libraries, Fragment-Based Screening & AI to Effectively Find Hits for Hard-to-Drug Targets

In today’s high-stakes world of drug discovery, the pressure to uncover effective treatments is reaching new heights. A central hurdle lies in finding promising lead compounds – those critical ‘hits’ capable of interacting with notoriously difficult targets.

That’s where the 2nd Hit ID Summit steps in, designed for forward-thinking discovery teams to enable a focused platform for evaluating and refining hit screening strategies. Through detailed case studies and collaborative discussions, you will gain insights into what’s been tried and what’s to come for validating hits using ASMS and biophysical techniques, and tackling hard-to-drug PPIs, transcription factors, and RNA.

With 60+ medicinal and computational chemists, molecular biologists, biophysicists, and drug discovery decision makers reuniting this September, this forum is your chance to delve into practical strategies for leveraging AI to enhance virtual screening, innovating DELs and fragment-based approaches, as well as building diverse chemical libraries to improve hit-finding success.

In the race to bring novel therapies to market, identifying viable drug candidates remains a priority across many therapeutic indications, highlighting the need for more efficient and effective screening strategies.

2025 Expert Speakers Include:

• Chloe Jones
  Principal Scientist, Encoded Technologies
  GlaxoSmithKline
• Fabien Vincent
  Research Fellow & Laboratory Head
  Pfizer
• William Mallender
  Senior Vice President, Biochemistry
  Tango Therapeutics
• Hans-Peter Biemann
  Distinguished Scientist & Scientific Director
  Sanofi
• and many others